Navigation Links
Antibody Helps Repair MS Nerve Damage
Date:10/10/2007

Promising results in mice need to be repeated in humans, experts say

WEDNESDAY, Oct. 10 (HealthDay News) -- Researchers say they've made new strides in harnessing the body's natural ability to reverse nerve damage wrought by multiple sclerosis.

According to the U.S. team, a single low dose of a human antibody administered to laboratory mice repaired myelin, the protective sheath that covers nerves. Multiple sclerosis wreaks havoc with the nervous system by stripping away this outer covering.

"This is an exciting first step in increasing our knowledge of repair in multiple sclerosis using a unique approach," said Patricia O'Looney, vice president of biomedical research programs at the National Multiple Sclerosis Society (NMSS) in New York City, which helped fund the research.

The findings were presented Tuesday at the annual meeting of the American Neurological Association, in Washington, D.C.

In healthy individuals, damage to myelin repairs itself naturally. But in people with MS and other disorders of the central nervous system, myelin repair occurs either slowly or not at all. As a result, the flow of information between the brain and the rest of the body is impaired, resulting in movement problems.

Some 400,000 people in the United States and 2.5 million people globally have been diagnosed with MS, most of them between the ages of 20 and 50, according to the NMSS.

"The challenge for researchers in trying to get a cure is, how do we repair myelin and restore function?" O'Looney said.

There is some evidence that cells that produce myelin are still present around damaged areas. As O'Looney put it, "The cells are already there, so how do you stimulate them to do what they're supposed to be doing?"

For this study, researchers at the Mayo Clinic in Rochester, Minn., genetically engineered a special antibody, called rHIgM22. This antibody binds to myelin and the surface of cells in the brain and spinal cord, prompting those cells to begin the process of remyelination.

The antibody is the first known compound to spur repair by acting within the central nervous system.

Laboratory mice that received a single dose of the antibody experienced remyelination that plateaued within five weeks.

When combined with a steroid (often prescribed for patients with MS), the antibody continued to promote remyelination, the research team said. Most human patients who might receive the antibody one day in the future will have already been treated with this steroid, they noted.

The antibodies did not appear to have any side effects, even at 4,000 times the minimal effective dose.

The Mayo team will eventually have to replicate the findings in humans before the concept can become an effective therapy, experts say.

"This approach is trying to use a naturally occurring molecule in our body in such a way that it binds to the cell and triggers signals within the cell to begin the repair process," O'Looney said. "This is a very exciting area of research in MS. How do you stimulate natural repair? How do you stimulate cells already there to repair the damage that's done? This is a unique, different way of approaching that, and it seems to be very successful in one of the animal models of MS."

More information

For more on multiple sclerosis, visit the National Multiple Sclerosis Society.



SOURCES: Patricia O'Looney, Ph.D., vice president, biomedical research programs, National Multiple Sclerosis Society, New York City; Oct. 9, 2007, presentation, American Neurological Association annual meeting, Washington, D.C.


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Stroke risk might be linked to antibody
2. Human Antibody That Can Block SARS
3. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
4. Cancer killing antibody effective against prostate cancer
5. Cuba Registers New Antibody
6. Single Sugar Enables Antibody to Treat Inflammation
7. Monoclonal Antibody based system for Anthrax detection
8. Monoclonal Antibody Reduces Exacerbations in Asthmatics
9. Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels
10. Antibody Therapy Prevents Type 1 Diabetes
11. New Antibody for EGFR Causes Lung Cancer Regression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... ... in North America for the scientific development, healthcare training and clinical application of ... & Scientific Session on September 16-17 in Greenville, SC at the Bon Secours ...
(Date:2/28/2017)... (PRWEB) , ... February 28, 2017 , ... Las Vegas ... revamped South Rancho location on Friday, March 10, 2017, 4-7 pm PST. For more ... but this clinic, located in the South Rancho neighborhood, has been renovated to provide ...
(Date:2/28/2017)... (PRWEB) , ... February 28, 2017 , ... BrightStar Care ... of Choice Awards from Home Care Pulse. This award is granted only to top-ranking ... BrightStar Care Marietta is now ranked among home care providers from across the ...
(Date:2/27/2017)... ... 2017 , ... Bo Chen, PhD is the recipient of the 2017 ASLMS ... the Plenary Session at ASLMS 2017, the Annual Conference of the American Society for ... 5-9, 2017. , During the Plenary Session on April 7, Dr. Chen will ...
(Date:2/27/2017)... , ... February 27, 2017 , ... Robert E. Burke, ... medical group. But his impoverished upbringing and life experiences could have led him down ... Physician: Insightful and Inspirational Tales of Parenting, Perseverance and Pediatrics,” Dr. Burke shares a ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... ... and Markets has announced the addition of the "Active Pharmaceutical ... The global active pharmaceutical ingredients (API) market is ... The rising prevalence of lifestyle-induced & age-related diseases and cancer is ... recombinant molecular technologies and high capitalization for development of novel drugs ...
(Date:2/28/2017)... SINGAPORE and SAN FRANCISCO , February 27, 2017 ... four Se D ... portfolio of biotechnology assets   LOI contemplates capital ... term growth plan for building shareholder value   Amarantus names ... interim-CFO of Amarantus   SeD Biomedical Inc. ...
(Date:2/28/2017)... February 28, 2017 The global  pulse oximeters market  is ... by Grand View Research, Inc. The pulse oximeters market is anticipated to witness ... prevalence of target diseases such as chronic obstructive pulmonary disease (COPD), sleep apnea, ... ... Grand View Research Logo ...
Breaking Medicine Technology: